Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Shionogi & Co. Ltd.

Orphan Drug, Domestic Developers Shine In China Annual Approvals Tally

10 orphan drugs imported from overseas, and 40 new drug approvals, including many from domestic developers, capped 2023 as one of the busiest years for China's drug regulatory agency, as Beijing pivoted to emphasizing affordable innovation and expanding access to newer therapies for rare conditions.

China Approvals

ViiV’s Cabenuva Could Find Niche In Non-Adherent HIV Patients

The company said results of the LATITUDE trial showed superiority for the long-acting injectable over daily oral pills in patients struggling with adherence to their HIV treatment regimens.

Clinical Trials Infectious Diseases

Korea Q4 Roundup: GC’s IVIG US Approval, SK Biopharm Turns Around

Aside from mixed earnings at major South Korean pharma firms, recent updates across the local industry have included the ongoing leadership dispute at Hanmi Group, the approval and reimbursement of Yuhan’s lazertinib as a first-line NSCLC therapy and the US approval of GC Biopharma’s immuno-globulin product.

South Korea Companies

Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances

More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.

Scrip Asks Advanced Therapies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Shionogi Healthcare Co., Ltd
    • Shionogi Pharma Co., Ltd
    • Shionogi Techno Advance Research Co., Ltd.
    • Shionogi Administration Service Co., Ltd.
    • Shionogi Business Partner Co., Ltd
    • Shionogi Marketing Solutions Co., Ltd
    • Shionogi Career Development Center Co., Ltd.
    • Shionogi Digital Science Co., Ltd.
    • Shionogi Pharmacovigilance Center Co., Ltd.
    • Aburahi AgroResearch Co., Ltd.
    • Shionogi Smile Heart Co., Ltd
    • UMN Pharma Inc.
    • Shionogi B.V.
UsernamePublicRestriction

Register